Doctor-led notes on rulings, enforcement, and the rules that govern claims.

UK health advertising is, in 2026, governed by a denser stack of rules than at any point in the last decade. The CAP Code (non-broadcast), the Human Medicines Regulations 2012, the MHRA Blue Guide, GPhC standards, the GB Nutrition and Health Claims Register and the Digital Markets, Competition and Consumers Act 2024 each apply, and frequently apply to the same surface at the same time.

Most published commentary on this stack is written by lawyers for other lawyers, or by agencies for other agencies. Verattia’s Insights feed is written from a third position: a clinician’s reading of the published rules, signed personally against a current GMC registration, intended to help brand, marketing and compliance teams write through the rules rather than around them.

What this feed covers

• ASA adjudications on UK pharmacy, aesthetics and consumer-health advertising, with the rule and the surface pattern named in plain language.
• MHRA enforcement notices and Blue Guide updates affecting prescription-only medicines, GLP‑1 advertising, and POM-adjacent funnels.
• GPhC standards and registrant guidance where the surface is pharmacist-fronted or pharmacy-owned.
• CAP Code rule changes, particularly section 12 (medicines, medical devices, treatments and health), section 13 (weight control), and section 15 (food and dietary supplements).
• Aesthetics-sector rulings covering botulinum toxin, dermal fillers, fat dissolution, threads and energy-based devices.
• Consumer-health and supplement claims against the GB NHCR and authorised-claim wording.
• Cross-regulator framework shifts where ASA, MHRA and GPhC publish jointly or in close sequence, often signalling a substantive change in what counts as a breach.

How the feed is structured

Two formats run on a single feed.

Rulings Watch notes are short, fast and dated. They are published within 48 hours of a ruling reaching the public ASA database or an MHRA / GPhC notice landing on gov.uk. Each note names the surface, the claim, the rule cited and the practical lesson for similar funnels. Most read in five minutes or less.

Analysis pieces are long-form. They are published when a frame shift, an enforcement pattern or a regulator alignment has moved the line. Analysis pieces include a wording bank where the published wording has demonstrably stopped working and a defensible replacement exists.

Every post lists its datePublished and dateModified in the metadata. Where a post is materially updated after a follow-on ruling, the dateline on the page moves with it and the change is noted at the top.

Editorial principles

• Primary sources only. Every claim about the rules links to the rule. ASA adjudications go to asa.org.uk; statute goes to legislation.gov.uk; regulator guidance goes to gov.uk or gmc-uk.org.
• Named author. Posts are signed by Dr Borna Farzaneh (GMC 7835999). No ghostwriting, no syndication.
• No legal advice. Posts are a clinician’s reading of published regulatory material. They are intended to inform internal review and conversations with regulatory counsel, not to substitute for them.
• Corrections welcomed. If a post misreads a primary source, send the correction to hello@verattia.com. Verified corrections are made on the page with a visible date.
• No paid commentary. Verattia does not accept fees, gifts or commercial sponsorship in exchange for coverage of a brand, ruling or product.

If a brand needs a doctor-led read of its own surfaces against the rules covered here, that work is delivered through the Rapid Risk Triage and Full Audit packages on the main site.